-
How to drug a cloud? Targeting intrinsically disordered proteins. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-10-21 Vladimir N Uversky
Biologically active proteins/regions without stable structure (i.e., intrinsically disordered proteins and regions (IDPs and IDRs)) are commonly found in all proteomes. They have a unique functional repertoire that complements the functionalities of ordered proteins and domains. IDPs/IDRs are multifunctional promiscuous binders capable of folding at interaction with specific binding partners on a template-
-
Ironing Out the Mechanism of gp130 Signaling Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Essam Eldin A. Osman, Nouri Neamati, Des Richardson
-
Intestinal Lymphatic Biology, Drug Delivery, and Therapeutics: Current Status and Future Directions Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Sanjeevini Babu Reddiar, Yining Xie, Mohammad Abdallah, Sifei Han, Luojuan Hu, Orlagh M. Feeney, Gracia Gracia, Abel Anshabo, Zijun Lu, Muhammad Asim Farooq, Ian K. Styles, Anthony R.J. Phillips, John A. Windsor, Christopher J.H. Porter, Enyuan Cao, Natalie L. Trevaskis, Rebecca Ritchie
Historically, the intestinal lymphatics were considered passive conduits for fluids, immune cells, dietary lipids, lipid soluble vitamins, and lipophilic drugs. Studies of intestinal lymphatic drug delivery in the late 20th century focused primarily on the drugs’ physicochemical properties, especially high lipophilicity, that resulted in intestinal lymphatic transport. More recent discoveries have
-
Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Karin E. Sandoval, Ken A. Witt, Kay Double
-
Posttranslational Modifications ofα-Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Kambiz Hassanzadeh, Jun Liu, Santhosh Maddila, M. Maral Mouradian, Kay Double
-
Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Tiangang Li, John Y.L. Chiang, Grace Guo
Bile acids are the end products of cholesterol catabolism. Hepatic bile acid synthesis accounts for a major fraction of daily cholesterol turnover in humans. Biliary secretion of bile acids generates bile flow and facilitates biliary secretion of lipids, endogenous metabolites, and xenobiotics. In intestine, bile acids facilitate the digestion and absorption of dietary lipids and fat-soluble vitamins
-
Drug-Drug Interactions and Synergy: From Pharmacological Models to Clinical Application Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Luigino Calzetta, Clive Page, Maria Gabriella Matera, Mario Cazzola, Paola Rogliani, Martin Michel
This review explores the concept of synergy in pharmacology, emphasizing its importance in optimizing treatment outcomes through the combination of drugs with different mechanisms of action. Synergy, defined as an effect greater than the expected additive effect elicited by individual agents according to specific predictive models, offers a promising approach to enhance therapeutic efficacy while minimizing
-
Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Rina Aharoni, Ron Milo, Ruth Arnon, Francesca Levi-Schaffer
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS), with a putative autoimmune origin and complex pathogenesis. Modification of the natural history of MS by reducing relapses and slowing disability accumulation was first attained in the 1990 s with the development of the first-generation disease-modifying therapies. Glatiramer
-
Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 F. Peter Guengerich, Ali Eid
Our knowledge of the roles of individual cytochrome P450 (P450) enzymes in drug metabolism has developed considerably in the past 30 years, and this base has been of considerable use in avoiding serious issues with drug interactions and issues due to variations. Some newer approaches are being considered for “phenotyping” metabolism reactions with new drug candidates. Endogenous biomarkers are being
-
The 75-Year Anniversary of the Department of Physiology and Pharmacology at Karolinska Institutet—Examples of Recent Accomplishments and Future Perspectives Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Eddie Weitzberg, Magnus Ingelman-Sundberg, Jon O. Lundberg, Göran Engberg, Gunnar Schulte, Volker M. Lauschke, Lynette Daws
Karolinska Institutet is a medical university encompassing 21 departments distributed across three departmental or campus groups. Pharmacological research has a long and successful tradition at the institute with a multitude of seminal findings in the areas of neuronal control of vasodilatation, cardiovascular pharmacology, neuropsychopharmacology, receptor pharmacology, and pharmacogenomics that resulted
-
Pharmacological Approaches to Hearing Loss Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Christopher R. Cederroth, Jonas Dyhrfjeld-Johnsen, Barbara Canlon, Gunnar Schulte
-
Nitric Oxide Signaling and Regulation in the Cardiovascular System: Recent Advances Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Mattias Carlström, Eddie Weitzberg, Jon O. Lundberg, Gunnar Schulte
Nitric oxide (NO) from endothelial NO synthase importantly contributes to vascular homeostasis. Reduced NO production or increased scavenging during disease conditions with oxidative stress contribute to endothelial dysfunction and NO deficiency. In addition to the classical enzymatic NO synthases (NOS) system, NO can also be generated via the nitrate-nitrite-NO pathway. Dietary and pharmacological
-
International Union of Basic and Clinical Pharmacology CXV: The Class F of G Protein-Coupled Receptors Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Gunnar Schulte, Eliot Ohlstein
-
Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities Pharmacol. Rev. (IF 19.3) Pub Date : 2024-11-01 Ana Pocivavsek, Robert Schwarcz, Sophie Erhardt, Gunnar Schulte
-
Summing Up Pharmacological Reviews' 75th Anniversary Year and a Look to the Future. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-10-16 Lynette C Daws
-
Cytochrome P450 Enzymes: The Old Pandora's Box with an Ever-Growing Hope for Therapy Optimization and Drug Development-Editorial. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-10-16 Ahmed F El-Yazbi,Ali H Eid
-
Seventy-Five Years of Interactions: The Department of Physiology and Pharmacology at Karolinska Institutet and Pharmacological Reviews. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-10-16 Gunnar Schulte
-
Promising tools for future drug discovery and development in antiarrhythmic therapy. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-10-15 Gema Mondejar-Parreño,Patricia Sanchez-Perez,Francisco Miguel Cruz,Jose Jalife
Arrhythmia refers to irregularities in the rate and rhythm of the heart, with symptoms spanning from mild palpitations to life-threatening arrhythmias and sudden cardiac death (SCD). The complex molecular nature of arrhythmias complicates the selection of appropriate treatment. Current therapies involve the use of antiarrhythmic drugs (class I-IV) with limited efficacy and dangerous side effects and
-
Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-10-15 Roman Tremmel,Daniel Hübschmann,Elke Schaeffeler,Sebastian Pirmann,Stefan Fröhling,Matthias Schwab
Precision cancer medicine is widely established, and numerous molecularly targeted drugs for various tumor entities are approved or in development. Personalized pharmacotherapy in oncology has so far been based primarily on tumor characteristics, e.g., somatic mutations. However, the response to drug treatment also depends on pharmacological processes summarized under the term ADME (absorption, distribution
-
Biochemistry, pharmacology and in vivo function of arginases. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-10-15 Sophia K Heuser,Junjie Li,Silke Pudewell,Anthea LoBue,Zhixin Li,Miriam M Cortese-Krott
Arginase catalyzes the hydrolysis of L-arginine into L-ornithine and urea. The two existing isoforms Arg1 and Arg2 show different cellular localizations and metabolic functions. Arginase activity is crucial for nitrogen detoxification in the urea cycle, synthesis of polyamines, and control of l-arginine bioavailability and nitric oxide production. Despite significant progress in the understanding of
-
Bioactives from marine resources as natural health products: A review. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-10-07 Sarusha Santhiravel,Deepika Dave,Fereidoon Shahidi
The oceans are a rich source of a myriad of structurally different and unique natural products that are mainly found in invertebrates with potential applications in different disciplines. Microbial infection and cancer are the leading causes of death worldwide. Discovery of new sources of therapy for microbial infections is an urgent requirement due to the emergence of pathogenic microorganisms that
-
International Union of Basic and Clinical Pharmacology. CXVIII. Update on the Nomenclature for Atypical Chemokine Receptors including ACKR5. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-10-07 Andy Chevigné,Daniel F Legler,Antal Rot,Silvano Sozzani,Martyna Szpakowska,Marcus Thelen
Chemokines signal through classical G protein-coupled receptors (GPCRs) to induce cell migration during development, immune homeostasis and multiple diseases. Over the last decade a subfamily of atypical chemokine receptors (ACKRs) was delineated from GPCRs based on their inability to trigger conventional G protein signaling or mediate cell migration in response to chemokines. These receptors nevertheless
-
Ferroptosis and pathogenesis of neuritic plaques in Alzheimer's Disease. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-10-07 Wolfgang J Streit,Leah Phan,Ingo Bechmann
Neuritic plaques are pathognomonic and terminal lesions of Alzheimer's Disease (AD). They embody AD pathogenesis because they harbor in one space critical pathologic features of the disease: amyloid deposits, neurofibrillary degeneration (NFD), neuroinflammation, iron accumulation. Neuritic plaques are thought to arise from the conversion of diffuse extracellular deposits of amyloid beta protein (Aβ)
-
Therapeutic advantage of combinatorial CAR T cell and chemo-therapies. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-10-07 Meghan B Ward,Amber B Jones,Giedre Krenciute
Chimeric antigen receptor (CAR) T cell therapies have transformed outcomes for many patients with hematological malignancies. However, some patients do not respond to CAR T cell treatment, and adapting CAR T cells for solid and brain tumors has been met with many challenges including a hostile tumor microenvironment and poor CAR T cell persistence. Thus, it is unlikely that CAR T cell therapy alone
-
Multi- and poly-pharmacology of carbonic anhydrase inhibitors. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-26 Claudiu T Supuran
Eight genetically distinct families of the enzyme carbonic anhydrase (CA, EC 4.2.1.1) were described in organisms allover the phylogenetic tree. They catalyze the hydration of CO2 to bicarbonate and protons, and are involved in pH regulation, chemosensing and metabolism. The 15 α-CA isoforms present in humans are pharmacological drug targets known for decades, their inhibitors being used as diuretics
-
Prospects for the convergence of polyphenols with pharmaceutical drugs in Type 2 Diabetes: challenges, risks, and strategies. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-26 S Allamreddy,M Arora,R Ganugula,R Friend,R Basu,M N V Ravi Kumar
Type 2 diabetes mellitus (T2DM) is a complex disease that can lead to a variety of life-threatening secondary health conditions. Current treatment strategies primarily revolve around tight glucose control that is difficult to achieve and often turns out to be dangerous due to possible hypoglycemic events. Numerous long-term studies have demonstrated that complex pathways, including low-grade inflammation
-
Emerging Pharmacotherapies for Obesity: A Systematic Review. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-20 Michail Kokkorakis,Marlene Chakhtoura,Caline Rhayem,Jana Al Rifai,Malak Ghezzawi,Laura Valenzuela-Vallejo,Christos S Mantzoros
The history of anti-obesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the
-
International Union of Basic and Clinical Pharmacology. CXVII: Taste 2 receptors: Structures, functions, activators and blockers. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-08-30 Maik Behrens
Bitter perception plays a critical role for the detection of potentially harmful substances in food items for most vertebrates. The detection of bitter compounds is facilitated by specialized receptors located in taste buds of the oral cavity. This work focuses on the receptors, including their sensitivities, structure-function relationships, agonists and antagonists. Moreover, the existence of numerous
-
Intestinal Barrier, Immunity and Microbiome: Partners in the Depression Crime Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Eva M. Medina-Rodríguez, José Martínez-Raga, Yolanda Sanz, Habibeh Khoshbouei
-
The Development of Cannabinoids as Therapeutic Agents in the United States Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Conor H. Murray, Brenda M. Gannon, Peter J. Winsauer, Ziva D. Cooper, Marcus S. Delatte, Matthew Banks
Cannabis is one of the oldest and widely used substances in the world. Cannabinoids within the cannabis plant, known as phytocannabinoids, mediate cannabis’ effects through interactions with the body’s endogenous cannabinoid system. This endogenous system, the endocannabinoid system, has important roles in physical and mental health. These roles point to the potential to develop cannabinoids as therapeutic
-
The Art of Finding the Right Drug Target: Emerging Methods and Strategies Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Zi-Chang Jia, Xue Yang, Yi-Kun Wu, Min Li, Debatosh Das, Mo-Xian Chen, Jian Wu, Martin Michel
Drug targets are specific molecules in biological tissues and body fluids that interact with drugs. Drug target discovery is a key component of drug discovery and is essential for the development of new drugs in areas such as cancer therapy and precision medicine. Traditional in vitro or in vivo target discovery methods are time-consuming and labor-intensive, limiting the pace of drug discovery. With
-
Pharmacology of Hydrogen Sulfide and Its Donors in Cardiometabolic Diseases Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Hai-Jian Sun, Qing-Bo Lu, Xue-Xue Zhu, Zhang-Rong Ni, Jia-Bao Su, Xiao Fu, Guo Chen, Guan-Li Zheng, Xiao-Wei Nie, Jin-Song Bian, Richard Ye
Cardiometabolic diseases (CMDs) are major contributors to global mortality, emphasizing the critical need for novel therapeutic interventions. Hydrogen sulfide (H2S) has garnered enormous attention as a significant gasotransmitter with various physiological, pathophysiological, and pharmacological impacts within mammalian cardiometabolic systems. In addition to its roles in attenuating oxidative stress
-
Conotoxins Targeting Voltage-Gated Sodium Ion Channels Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Shengrong Pei, Nan Wang, Zaoli Mei, Dongting Zhangsun, David J. Craik, J. Michael McIntosh, Xiaopeng Zhu, Sulan Luo, Thomas Gudermann
-
Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Benoît Delabays, Katerina Trajanoska, Joshua Walonoski, Vincent Mooser, Rhian Touyz
-
Topically Applied Therapies for the Treatment of Skin Disease: Past, Present, and Future Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Marc Brown, Adrian Williams, Robert P. Chilcott, Brendan Brady, Jon Lenn, Charles Evans, Lynn Allen, William J. McAuley, Mubinah Beebeejaun, Jasmin Haslinger, Claire Beuttel, Raquel Vieira, Florencia Guidali, Margarida Miranda, Clive Page
The purpose of this review is to summarize essential biological, pharmaceutical, and clinical aspects in the field of topically applied medicines that may help scientists when trying to develop new topical medicines. After a brief history of topical drug delivery, a review of the structure and function of the skin and routes of drug absorption and their limitations is provided. The most prevalent diseases
-
International Union of Basic and Clinical Pharmacology CXIV: Orexin Receptor Function, Nomenclature and Pharmacology Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Jyrki. P. Kukkonen, Laura H. Jacobson, Daniel Hoyer, Maiju K. Rinne, Stephanie L. Borgland, Eliot Ohlstein
-
International Union of Basic and Clinical Pharmacology. CXVI: NC-IUPHAR and Pharmacological Reviews: 30+ Years of Collaboration-Editorial. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-08-15 Eliot H Ohlstein
-
The Enduring Impact of Pharmacological Reviews-Editorial. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-08-15 David R Sibley
-
Generation of Comprehensive GPCR-Transducer-Deficient Cell Lines to Dissect the Complexity of GPCR Signaling Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-01 Ayaki Saito, Ryoji Kise, Asuka Inoue, Gunnar Schulte
G-protein–coupled receptors (GPCRs) compose the largest family of transmembrane receptors and are targets of approximately one-third of Food and Drug Administration–approved drugs owing to their involvement in almost all physiologic processes. GPCR signaling occurs through the activation of heterotrimeric G-protein complexes and β-arrestins, both of which serve as transducers, resulting in distinct
-
Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-01 Zhiwen Huang, Zachary Braunstein, Jun Chen, Yingying Wei, Xiaoquan Rao, Lingli Dong, Jixin Zhong, Clive Page
-
Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple Sclerosis Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-01 Gabriel Bsteh, Assunta Dal Bianco, Tobias Zrzavy, Thomas Berger, Harald Sitte
The objective is to comprehensively review novel pharmacotherapies used in multiple sclerosis (MS) and the possibilities they may carry for therapeutic improvement. Specifically, we discuss pathophysiological mechanisms worth targeting in MS, ranging from well known targets, such as autoinflammation and demyelination, to more novel and advanced targets, such as neuroaxonal damage and repair. To set
-
Hope on the Horizon: Promising Therapies for Steatotic Liver Disease Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-01 Amirhossein Sahebkar, Ali H. Eid
Steatotic liver disease (SLD) is a highly prevalent chronic liver disease with significant challenges for global health. The pathophysiology of SLD involves an interplay among genetic, endocrine, and metabolic factors. Successful management of SLD entails accurate diagnosis and disease monitoring through noninvasive methods such as advanced imaging techniques and biomarkers. Many emerging pharmacotherapies
-
Pharmacology and Precision Medicine-Preparing for the Next Era in Clinical Medicine-Editorial. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-06-14 Rhian M Touyz
-
Molecular Pathways Governing the Termination of Liver Regeneration Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Lianne R. de Haan, Rowan F. van Golen, Michal Heger, Martin Michel
-
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros, Ali Eid
-
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Wei Wang, Najah Albadari, Yi Du, Josef F. Fowler, Hannah T. Sang, Wa Xian, Frank McKeon, Wei Li, Jia Zhou, Ruiwen Zhang, Michael Gottesman
-
Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4 Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Ana Santiso, Akos Heinemann, Julia Kargl, Michael Gottesman
-
Adrenoceptor Desensitization: Current Understanding of Mechanisms Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Dina Maaliki, Aneese A. Jaffa, Suzanne Nasser, Amirhossein Sahebkar, Ali H. Eid, Paul Insel, Martin Michel
G-protein coupled receptors (GPCRs) transduce a wide range of extracellular signals. They are key players in the majority of biologic functions including vision, olfaction, chemotaxis, and immunity. However, as essential as most of them are to body function and homeostasis, overactivation of GPCRs has been implicated in many pathologic diseases such as cancer, asthma, and heart failure (HF). Therefore
-
New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Analia Bortolozzi, Giovanna Fico, Michael Berk, Marco Solmi, Michele Fornaro, Joao Quevedo, Carlos A. Zarate, Lars V. Kessing, Eduard Vieta, Andre F. Carvalho, Robert Dantzer
Over the last six decades, lithium has been considered the gold standard treatment for the long-term management of bipolar disorder due to its efficacy in preventing both manic and depressive episodes as well as suicidal behaviors. Nevertheless, despite numerous observed effects on various cellular pathways and biologic systems, the precise mechanism through which lithium stabilizes mood remains elusive
-
A Chance to Grow and Excel as an Associate Editor of Pharmacological Reviews-Editorial. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-02 Ali H Eid
-
The Arylamine N-Acetyltransferases as Therapeutic Targets in Metabolic Diseases Associated with Mitochondrial Dysfunction Pharmacol. Rev. (IF 19.3) Pub Date : 2024-03-01 Chandra Choudhury, Melinder K. Gill, Courtney E. McAleese, Neville J. Butcher, Shyuan T. Ngo, Frederik J. Steyn, Rodney F. Minchin, Michael Gottesman
In humans, there are two arylamine N-acetyltransferase genes that encode functional enzymes (NAT1 and NAT2) as well as one pseudogene, all of which are located together on chromosome 8. Although they were first identified by their role in the acetylation of drugs and other xenobiotics, recent studies have shown strong associations for both enzymes in a variety of diseases, including cancer, cardiovascular
-
The Role of G Protein-Coupled Receptors and Receptor Kinases in Pancreatic {beta}-Cell Function and Diabetes Pharmacol. Rev. (IF 19.3) Pub Date : 2024-02-13 Varney, M. J., Benovic, J. L.
Type 2 diabetes (T2D) mellitus has emerged as a major global health concern that has accelerated in recent years due to poor diet and lifestyle. Afflicted individuals have high blood glucose levels that stem from the inability of the pancreas to make enough insulin to meet demand. Although medication can help to maintain normal blood glucose levels in individuals with chronic disease, many of these
-
Protecting Human and Animal Health: The Road from Animal Models to New Approach Methods Pharmacol. Rev. (IF 19.3) Pub Date : 2024-02-13 Kaplan, B. L. F., Hoberman, A. M., Slikker, W., Smith, M. A., Corsini, E., Knudsen, T. B., Marty, M. S., Sobrian, S. K., Fitzpatrick, S. C., Ratner, M. H., Mendrick, D. L.
Animals and animal models have been invaluable for our current understanding of human and animal biology, including physiology, pharmacology, biochemistry, and disease pathology. However, there are increasing concerns with continued use of animals in basic biomedical, pharmacological, and regulatory research to provide safety assessments for drugs and chemicals. There are concerns that animals do not
-
Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes Pharmacol. Rev. (IF 19.3) Pub Date : 2024-03-01 K.T. Babalola, M. Arora, R. Ganugula, S.K. Agarwal, C. Mohan, M.N.V. Ravi Kumar, Francesca Levi-Schaffer
The role of advanced drug delivery strategies in drug repositioning and minimizing drug attrition rates, when applied early in drug discovery, is poised to increase the translational impact of various therapeutic strategies in disease prevention and treatment. In this context, drug delivery to the lymphatic system is gaining prominence not only to improve the systemic bioavailability of various pharmaceutical
-
Emergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust Pharmacol. Rev. (IF 19.3) Pub Date : 2024-03-01 Ashish Kumar, Michael A. Nader, Gagan Deep, Andrew Baker
-
A 25-Year Journey as Author and Associate Editor of Pharmacological Reviews-Editorial. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-02-13 Martin C Michel
-
The SLC6A15–SLC6A20 Neutral Amino Acid Transporter Subfamily: Functions, Diseases, and Their Therapeutic Relevance Pharmacol. Rev. (IF 19.3) Pub Date : 2024-01-01 Jędrzej Kukułowicz, Krzysztof Pietrzak-Lichwa, Klaudia Klimończyk, Nathalie Idlin, Marek Bajda, Habibeh Khoshbouei
-
Halogenated Antimicrobial Agents to Combat Drug-Resistant Pathogens Pharmacol. Rev. (IF 19.3) Pub Date : 2024-01-01 Olajide Sunday Faleye, Bharath Reddy Boya, Jin-Hyung Lee, Inho Choi, Jintae Lee, Clive Page
-
Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin Pharmacol. Rev. (IF 19.3) Pub Date : 2024-01-01 Anagha Gogate, Jordyn Belcourt, Milan Shah, Alicia Zongxun Wang, Alexis Frankel, Holly Kolmel, Matthew Chalon, Prajith Stephen, Aarush Kolli, Sherouk M. Tawfik, Jing Jin, Raman Bahal, Theodore P. Rasmussen, José E. Manautou, Xiao-bo Zhong, Grace Guo
-
Nonhormonal Male Contraceptive Development--Strategies for Progress Pharmacol. Rev. (IF 19.3) Pub Date : 2023-12-15 Nickels, L., Yan, W.
Despite the widely demonstrated public health benefits of contraception, limited contraceptive options are available for men, placing both the contraceptive burden and opportunity solely on women. This review outlines the need for an increased focus on male contraceptive development and highlights several related topics, including the perspectives of women and men on male contraceptives, historical